SK Biopharmaceuticals bets up to $795m on Biohaven’s opakalim before pivotal data
SK Biopharmaceuticals is acquiring worldwide rights to opakalim and Biohaven’s Kv7 platform, providing $400 million in near-term cash and assuming additional obligations while pivotal RISE3 data remain due in the second half of 2026.